6th Annual Gulf-Atlantic Veterinary Conference
Gastrointestinal (GI) cancers often have a profound clinical impact and advanced progression at the time of diagnosis making a positive clinical outcome challenging. Limited information has been historically available regarding best treatment strategies and expected outcomes. Recent findings and growing utilization of newer therapeutics are expanding available options. Discussion will focus on new data regarding the use of tyrosine kinase inhibitors in the management of canine gastrointestinal stromal tumours (GIST) and carcinomas, as well as feline mast cell neoplasia. Recent insights regarding the potential role of the GI microbiota in feline GI lymphoma development and how this may impact our therapeutic strategies will be explored. Updated thoughts on the therapeutic approach to GI lymphoma in dogs will also be reviewed.